Expression of MMP‐2, MMP‐9, and Urokinase‐Type Plasminogen Activator in Cervical Intraepithelial Neoplasia
- 15 August 2009
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1171 (1) , 100-104
Abstract
Matrix metalloproteinase‐2 (MMP‐2), MMP‐9, and urokinase‐type plasminogen activator (uPA) are important factors for cancer invasion and metastasis, degrading the extracellular matrix. They are also associated with angiogenesis. Angiogenic phenotype is another feature of high‐grade cervical intraepithelial neoplasia (CIN). However, their associations with the progression of low‐grade CIN to high‐grade CIN are unexplored. We investigated whether these proteolytic enzyme expressions correlate with the progression of CIN. A total of 39 paraffin‐embedded specimens from 10 patients with CIN grade 1, nine with CIN grade 2, and 20 with CIN grade 3 were assessed immunohistochemically by specific antibodies against MMP‐2, MMP‐9, and uPA. MMP‐9 expression was higher in CIN 3 lesions (47.4%) than in CIN 1 (22.2%) and CIN 2 (20.2%) lesions, although the difference failed to reach statistical significance. The expression level of uPA and MMP‐2 was not associated with the grade of CIN lesions. Interestingly, we found a significant association between expressions of uPA and MMP‐2 (P= 0.028). Our results suggest that MMP‐9 might play a role in the progression of CIN.Keywords
This publication has 16 references indexed in Scilit:
- A Significant Elevation of Plasma Level of Matrix Metalloproteinase—9 in Patients With High-Grade Intraepithelial Neoplasia and Early Squamous Cell Carcinoma of the Uterine CervixReproductive Sciences, 2007
- Worldwide burden of gynaecological cancer: The size of the problemBest Practice & Research Clinical Obstetrics & Gynaecology, 2006
- Matrix metalloproteinases and tumor metastasisCancer and Metastasis Reviews, 2006
- Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapyNature Reviews Cancer, 2006
- HPV‐mediated cervical carcinogenesis: concepts and clinical implicationsThe Journal of Pathology, 2005
- Matrix metalloproteinases and angiogenesisJournal of Cellular and Molecular Medicine, 2005
- Comparative study of MMP-2 (matrix metalloproteinase 2) immune expression in normal uterine cervix, intraepithelial neoplasias, and squamous cells cervical carcinomaAmerican Journal of Obstetrics and Gynecology, 2004
- MMP-1 and MMP-2 in the Cervix Uteri in Different Steps of Malignant Transformation—An Immunohistochemical StudyGynecologic Oncology, 2002
- MMP-2 and TIMP-2 Expression Correlates with Poor Prognosis in Cervical Carcinoma—A Clinicopathologic Study Using Immunohistochemistry and mRNA in Situ HybridizationGynecologic Oncology, 1999
- Vascular Permeability Factor (Vascular Endothelial Growth Factor) Expression and Angiogenesis in Cervical NeoplasiaJNCI: Journal of the National Cancer Institute, 1995